Research progress of antibody-dependent enhancement of human coronaviruses

doi:10.3969/j.issn.1673-8640.2021.03.023

Abstract

Abstract:

Antibody-dependent enhancement（ADE） of viral entry has been a major concern for epidemiology,vaccine development and antibody-based drug therapy. ADE of coronavirus replication is believed to occur when antibodies mediate coronavirus to bind to its viral receptor or Fc receptor（FcR） to enhance viral infection in some certain cases. ADE is regulated by a series of complex factors of the virus and the host,such as the structure of spike protein,the affinity with receptor and the titer of antibody of coronavirus. In this review,the present advances of ADE in human coronaviruses were discussed to provide reference for the subsequent vaccine design,antibody-related drugs,and immunotherapy.

Key words: Coronavirus, Severe acute respiratory syndrome-related coronavirus, Middle east respiratory syndrome-related coronavirus, Severe acute respiratory syndrome coronavirus 2, Antibody-dependent enhancement, Vaccines

CLC Number:

R446.1

YUAN Mengjiao, YU Qian, WANG Beili, PAN Baishen, GUO Wei. Research progress of antibody-dependent enhancement of human coronaviruses[J]. Laboratory Medicine, 2021, 36(3): 341-346.

References 47

[1]	ENJUANES L, ALMAZÁN F, SOLA I, et al. Biochemical aspects of coronavirus replication and virus-host interaction[J]. Annu Rev Microbiol, 2006,60:211-230. DOI URL PMID
[2]	ZHONG N S, ZHENG B J, LI Y M, et al. Epidemiology and cause of severe acute respiratory syndrome(SARS) in Guangdong,People's Republic of China,in February,2003[J]. Lancet, 2003,362(9393):1353-1358.
[3]	中华人民共和国卫生健康委员会办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版)[J]. 中国医药, 2020,15(6):801-805.
[4]	MUNSTER V J, KOOPMANS M, VAN DOREMALEN N, et al. A novel coronavirus emerging in China-key questions for impact assessment[J]. N Engl J Med, 2020,382(8):692-694. DOI URL PMID
[5]	ZHOU P, YANG X L, WANG X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798):270-273. DOI URL PMID
[6]	WANG F S, ZHANG C. What to do next to control the 2019-nCoV epidemic?[J]. Lancet, 2020,395(10222):391-393. DOI URL PMID
[7]	KUZMINA N A, YOUNAN P, GILCHUK P, et al. Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors[J]. Cell Rep, 2018,24(7):1802-1815 e5. DOI URL PMID
[8]	WILLEY S, AASA-CHAPMAN M M I, O'FARRELL S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection[J]. Retrovirology, 2011,8:16. DOI URL PMID
[9]	TAKADA A, KAWAOKA Y. Antibody-dependent enhancement of viral infection:molecular mechanisms and in vivo implications[J]. Rev Med Virol, 2003,13(6):387-398. DOI URL PMID
[10]	VENNEMA H, DE GROOT R J, HARBOUR D A, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization[J]. J Virol, 1990,64(3):1407-1409. URL PMID
[11]	HAWKES R A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls[J]. Aust J Exp Biol Med Sci, 1964,42:465-482. URL PMID
[12]	WEISS R C, SCOTT F W. Antibody-mediated enhancement of disease in feline infectious peritonitis:comparisons with dengue hemorrhagic fever[J]. Comp Immunol Microbiol Infect Dis, 1981,4(2):175-189. DOI URL PMID
[13]	DANIEL C, TALBOT P J. Protection from lethal coronavirus infection by affinity-purified spike glycoprotein of murine hepatitis virus,strain A59[J]. Virology, 1990,174(1):87-94. DOI URL PMID
[14]	OLSEN C W, CORAPI W V, NGICHABE C K, et al. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages[J]. J Virol, 1992,66(2):956-965. URL PMID
[15]	LI F. Structure,function,and evolution of coronavirus spike proteins[J]. Annu Rev Virol, 2016,3(1):237-261. URL PMID
[16]	WALLS A C, PARK Y J, TORTORICI M A, et al. Structure,function,and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020,181(2):281-292. DOI URL PMID
[17]	YIP M S, LEUNG N H, CHEUNG C Y, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus[J]. Virol J, 2014,11:82. URL PMID
[18]	LIU L, WEI Q, LIN Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J]. JCI Insight, 2019,4(4):e123158.
[19]	AGRAWAL A S, TAO X, ALGAISSI A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J]. Hum Vaccin Immunother, 2016,12(9):2351-2356. DOI URL PMID
[20]	CHEUNG C Y, POON L L M, NG I H Y, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro:possible relevance to pathogenesis[J]. J Virol, 2005,79(12):7819-7826. DOI URL PMID
[21]	CHAN K H, CHAN J F W, TSE H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC(2012) by both immunofluorescent and neutralizing antibody tests[J]. J Infect, 2013,67(2):130-140. URL PMID
[22]	JAUME M, YIP M S, CHEUNG C Y, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway[J]. J Virol, 2011,85(20):10582-10597.
[23]	BALSITIS S J, WILLIAMS K L, LACHICA R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification[J]. PLoS Pathog, 2010,6(2):e1000790. DOI URL PMID
[24]	WAN Y, SHANG J, SUN S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J]. J Virol, 2020,94(5):e02015-e02019. DOI URL PMID
[25]	CARDOSA M J, PORTERFIELD J S, GORDON S. Complement receptor mediates enhanced flavivirus replication in macrophages[J]. J Exp Med, 1983,158(1):258-263. URL PMID
[26]	ROBINSON W E Jr, MONTEFIORI D C, GILLESPIE D H, et al. Complement-mediated,antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release[J]. J Acquir Immune Defic Syndr(1988), 1989,2(1):33-42.
[27]	PROHÁSZKA Z, NEMES J, HIDVÉGI T, et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection[J]. AIDS, 1997,11(8):949-958. DOI URL PMID
[28]	JIANG S, HILLYER C, DU L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses[J]. Trends Immunol, 2020,41(5):355-359. DOI URL PMID
[29]	CHEN Z, ZHANG L, QIN C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. J Virol, 2005,79(5):2678-2688. URL PMID
[30]	YUAN Y, CAO D, ZHANG Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains[J]. Nat Commun, 2017,8:15092. DOI URL PMID
[31]	WALLS A C, XIONG X, PARK Y J, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion[J]. Cell, 2019,176(5):1026-1039 e1015. DOI URL PMID
[32]	WANG S F, TSENG S P, YEN C H, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins[J]. Biochem Biophys Res Commun, 2014,451(2):208-214. DOI URL PMID
[33]	YANG Z Y, WERNER H C, KONG W P, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses[J]. Proc Natl Acad Sci U S A, 2005,102(3):797-801. DOI URL PMID
[34]	MATHEWSON A C, BISHOP A, YAO Y, et al. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2[J]. J Gen Virol, 2008,89(Pt 11):2741-2745. DOI URL PMID
[35]	WRAPP D, WANG N, CORBETT K S, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020,367(6483):1260-1263. URL PMID
[36]	YAN R, ZHANG Y, LI Y, et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2[J]. Science, 2020,367(6485):1444-1448. DOI URL PMID
[37]	LIU W, FONTANET A, ZHANG P H, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome[J]. J Infect Dis, 2006,193(6):792-795. DOI URL PMID
[38]	LIU W J, ZHAO M, LIU K, et al. T-cell immunity of SARS-CoV:implications for vaccine development against MERS-CoV[J]. Antiviral Res, 2017,137:82-92. DOI URL PMID
[39]	KATZELNICK L C, GRESH L, HALLORAN M E, et al. Antibody-dependent enhancement of severe dengue disease in humans[J]. Science, 2017,358(6365):929-932. DOI URL PMID
[40]	WEINGARTL H, CZUB M, CZUB S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets[J]. J Virol, 2004,78(22):12672-12676. DOI URL PMID
[41]	CZUB M, WEINGARTL H, CZUB S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets[J]. Vaccine, 2005,23(17-18):2273-2279. DOI URL PMID
[42]	DU L, TAI W, ZHOU Y, et al. Vaccines for the prevention against the threat of MERS-CoV[J]. Expert Rev Vaccines, 2016,15(9):1123-1134. URL PMID
[43]	STRIZOVA Z, SMETANOVA J, BARTUNKOVA J, et al. Principles and challenges in anti-COVID-19 vaccine development[J/OL]. Int Arch Allergy Immunol 2021:1-11. (2021-02-01)[2021-02-01]. https://www.karger.com/Article/FullText/514225.
[44]	ROPER R L, REHM K E. SARS vaccines:where are we?[J]. Expert Rev Vaccines, 2009,8(7):887-898. URL PMID
[45]	DU L, TAI W, YANG Y, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines[J]. Nat Commun, 2016,7:13473. DOI URL PMID
[46]	OKBA N M, RAJ V S, HAAGMANS B L. Middle East respiratory syndrome coronavirus vaccines:current status and novel approaches[J]. Curr Opin Virol, 2017,23:49-58. DOI URL PMID
[47]	TSENG C T, HUANG C, NEWMAN P, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human angiotensin-converting enzyme 2 virus receptor[J]. J Virol, 2007,81(3):1162-1173. DOI URL PMID